Novel nonstatin strategies to lower low-density lipoprotein cholesterol
- 17 December 2008
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 11 (1) , 67-70
- https://doi.org/10.1007/s11883-009-0011-0
Abstract
There remains an unmet need to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients who are maximized on current therapy or intolerant to statins. Several novel agents have been developed to lower LDL-C, either as monotherapy or in combination with statins. These novel therapies include squalene synthase inhibitors, microsomal triglyceride transfer protein inhibitors, and antisense apolipoprotein B. Although each of these novel therapies effectively lowers LDL-C, challenges remain in the clinical development to assess long-term safety.Keywords
This publication has 14 references indexed in Scilit:
- Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemiaNature Clinical Practice Cardiovascular Medicine, 2008
- Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigsToxicology and Applied Pharmacology, 2007
- Antisense apolipoprotein B therapy: where do we stand?Current Opinion in Lipidology, 2007
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic miceJournal of Lipid Research, 2007
- Squalene synthase inhibition: A novel target for the management of dyslipidemiaCurrent Atherosclerosis Reports, 2007
- A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein CholesterolAmerican Journal of Human Genetics, 2006
- Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group RecommendationsThe American Journal of Cardiology, 2005
- Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol AbsorptionScience, 2004
- Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663British Journal of Pharmacology, 2000
- Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol AbsorptionJournal of Medicinal Chemistry, 1998